Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/30446| Title: | Drug-mediated and cellular immunotherapy in multiple myeloma. | Authors: | Neeson P.;Ritchie D.S.;Quach H.;Fielding K. | Institution: | (Ritchie, Quach, Fielding, Neeson) Haematology and Immunology Translational Research Laboratory, Cancer Immunology Research Program, Locked Bag 1, ABeckett St, East Melbourne, VIC 8000, Australia (Ritchie) Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, ABeckett St, East Melbourne, VIC 8000, Australia (Ritchie) University of Melbourne, Parkville, VIC, Australia (Quach) Monash Medical Centre, Clayton, VIC, Australia | Issue Date: | 27-May-2010 | Copyright year: | 2010 | Publisher: | Future Medicine Ltd. (E-mail: info@futuremedicine.com) | Place of publication: | United Kingdom | Publication information: | Immunotherapy. 2 (2) (pp 243-255), 2010. Date of Publication: March 2010. | Journal: | Immunotherapy | Abstract: | Multiple myeloma is an immunologically relevant disease, which subverts and suppresses immunity, but that may also be amenable to immunological control. Novel drug and cell-based therapies provide an opportunity for the design of antimyeloma immunotherapy. Reversing the immunosuppression associated myeloma remains a substantial challenge. The minimal residual disease setting achieved by autologous stem cell transplant or highly efficacious induction therapy may reverse this immunoparesis and provide a setting for induction of antimyeloma T-cell responses. Adoptive cytotoxic T-lymphocyte/NK therapy and comprehensive treatment with immunomodulatory drug therapy represent means by which antimyeloma immune responses may be promoted. In addition, apoptosis-inducing therapies may prime endogenous antigen presentation via immunogenic cell death, which again may be enhanced by the addition of immunomodulatory drug therapy. © 2010 Future Medicine Ltd. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2217/imt.10.9 | PubMed URL: | 20635931 [http://www.ncbi.nlm.nih.gov/pubmed/?term=20635931] | ISSN: | 1750-743X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/30446 | Type: | Review | Subjects: | drug efficacy drug megadose drug safety drug tolerability follicular lymphoma/dt [Drug Therapy] graft versus host reaction/co [Complication] human immune response immunogenicity immunosuppressive treatment in vivo study mediator *multiple myeloma/dt [Drug Therapy] *multiple myeloma/rt [Radiotherapy] *multiple myeloma/th [Therapy] multiple myeloma/dt [Drug Therapy] natural killer cell nonhuman plasmapheresis priority journal prognosis regulatory T lymphocyte review T lymphocyte treatment outcome anthracycline/cb [Drug Combination] anthracycline/dt [Drug Therapy] anthracycline/pd [Pharmacology] antigen/ec [Endogenous Compound] antineoplastic agent/do [Drug Dose] antineoplastic agent/dt [Drug Therapy] bortezomib/dt [Drug Therapy] bortezomib/pd [Pharmacology] cancer vaccine/dt [Drug Therapy] corticosteroid/cb [Drug Combination] corticosteroid/do [Drug Dose] corticosteroid/dt [Drug Therapy] dendritic cell vaccine/dt [Drug Therapy] dendritic cell vaccine/pd [Pharmacology] fluorouracil/cb [Drug Combination] fluorouracil/dt [Drug Therapy] fluorouracil/pd [Pharmacology] gemcitabine/cb [Drug Combination] gemcitabine/dt [Drug Therapy] gemcitabine/pd [Pharmacology] granulocyte macrophage colony stimulating factor/cb [Drug Combination] granulocyte macrophage colony stimulating factor/dt [Drug Therapy] immunoglobulin/dt [Drug Therapy] immunoglobulin/iv [Intravenous Drug Administration] immunomodulating agent/dt [Drug Therapy] immunosuppressive agent/dt [Drug Therapy] interleukin 12/cb [Drug Combination] interleukin 12/dt [Drug Therapy] interleukin 6 antibody/dt [Drug Therapy] lenalidomide/cb [Drug Combination] lenalidomide/dt [Drug Therapy] lenalidomide/pd [Pharmacology] monoclonal antibody/dt [Drug Therapy] Pneumococcus vaccine pomalidomide/cb [Drug Combination] pomalidomide/dt [Drug Therapy] pomalidomide/pd [Pharmacology] rituximab/dt [Drug Therapy] rituximab/pd [Pharmacology] taxane derivative/cb [Drug Combination] taxane derivative/dt [Drug Therapy] taxane derivative/pd [Pharmacology] thalidomide/cb [Drug Combination] thalidomide/dt [Drug Therapy] thalidomide/pd [Pharmacology] unclassified drug immune paralysis monoclonal antibody LeY/ct [Clinical Trial] monoclonal antibody LeY/dt [Drug Therapy] minimal residual disease *adoptive immunotherapy allogeneic stem cell transplantation antigen presentation antineoplastic activity apoptosis autologous stem cell transplantation cancer immunization cancer radiotherapy cell death cell growth cell proliferation cell survival *cell therapy clinical trial cytotoxic T lymphocyte dendritic cell cytotoxic T lymphocyte dendritic cell drug efficacy drug megadose drug safety drug tolerability follicular lymphoma / drug therapy graft versus host reaction / complication human immune response immunogenicity immunosuppressive treatment in vivo study mediator minimal residual disease *multiple myeloma / *drug therapy / *radiotherapy / *therapy multiple myeloma / drug therapy natural killer cell nonhuman plasmapheresis priority journal prognosis regulatory T lymphocyte review autologous stem cell transplantation treatment outcome apoptosis antineoplastic activity antigen presentation allogeneic stem cell transplantation *adoptive immunotherapy T lymphocyte cancer immunization cancer radiotherapy cell death cell growth cell proliferation cell survival *cell therapy clinical trial |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.